Breast Cancer Clinical Trial

Observational Study of Bone Complications in People With Post-menopausal Breast Cancer Who Have Stopped Treatment With Denosumab and Aromatase Inhibitors

Summary

The purpose of this study to gather information about changes in the bones after stopping treatment with aromatase inhibitor/AI and denosumab. The study team will collect information from 5 standard clinic visits over the course of 24 months. The information will include information about participant health assessments, blood test results, and imaging results. After 24 months, participation in this study will be complete.

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

Women with confirmed diagnosis of breast cancer
Participant must be post-menopausal, defined as last menstrual cycle at least 12 months prior to enrollment
Received at least 2 doses of denosumab and then discontinued therapy
Discontinued AI prior to or within 6 months of last denosumab injection
Patients must be 18 years of age or olde

Exclusion Criteria:

Patients with history of osteoporosis prior to starting denosumab, based on previous dual-energy X-ray absorptiometry (DEXA) scan;
Patients with history of insufficiency fracture.
Patients who continue treatment with a different bone modifying agent (i.e oral or intravenous bisphosphonates) after discontinuation of denosumab
Patients on chronic low-dose glucosteroids.

Study is for people with:

Breast Cancer

Estimated Enrollment:

100

Study ID:

NCT05590949

Recruitment Status:

Recruiting

Sponsor:

Memorial Sloan Kettering Cancer Center

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There are 7 Locations for this study

See Locations Near You

Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities)
Basking Ridge New Jersey, 07920, United States More Info
Monica Fornier, MD
Contact
646-888-4563
Memoral Sloan Kettering Monmouth (Limited Protocol Activities)
Middletown New Jersey, 07748, United States More Info
Monica Fornier, MD
Contact
646-888-4563
Memorial Sloan Kettering Bergen (Limited Protocol Activities)
Montvale New Jersey, 07645, United States More Info
Monica Fornier, MD
Contact
646-888-4563
Memorial Sloan Kettering Cancer Center @ Suffolk-Commack (Limited protocol activities)
Commack New York, 11725, United States More Info
Monica Fornier, MD
Contact
646-888-4563
Memoral Sloan Kettering Westchester (Limited Protocol Activities)
Harrison New York, 10604, United States More Info
Monica Fornier, MD
Contact
646-888-4563
Memorial Sloan Kettering Cancer Center
New York New York, 10065, United States More Info
Monica Fornier, MD
Contact
646-888-5240
Memorial Sloan Kettering Nassau (Limited Protocol Activities)
Uniondale New York, 11553, United States More Info
Monica Fornier, MD
Contact
646-888-4563

How clear is this clinincal trial information?

Study is for people with:

Breast Cancer

Estimated Enrollment:

100

Study ID:

NCT05590949

Recruitment Status:

Recruiting

Sponsor:


Memorial Sloan Kettering Cancer Center

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.